Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Liabilities and Shareholders Equity (2016 - 2025)

OptimizeRx (OPRX) has disclosed Liabilities and Shareholders Equity for 16 consecutive years, with $176.9 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 3.36% to $176.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $684.3 million through Dec 2025, changed 0.2% year-over-year, with the annual reading at $176.9 million for FY2025, 3.36% up from the prior year.
  • Liabilities and Shareholders Equity hit $176.9 million in Q4 2025 for OptimizeRx, up from $170.3 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $183.4 million in Q4 2023 to a low of $121.3 million in Q2 2023.
  • Historically, Liabilities and Shareholders Equity has averaged $151.1 million across 5 years, with a median of $144.2 million in 2021.
  • Biggest five-year swings in Liabilities and Shareholders Equity: surged 144.17% in 2021 and later dropped 17.72% in 2023.
  • Year by year, Liabilities and Shareholders Equity stood at $141.0 million in 2021, then dropped by 4.49% to $134.7 million in 2022, then soared by 36.18% to $183.4 million in 2023, then decreased by 6.66% to $171.2 million in 2024, then grew by 3.36% to $176.9 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for OPRX at $176.9 million in Q4 2025, $170.3 million in Q3 2025, and $169.3 million in Q2 2025.